Statistics for Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Total visits
| views | |
|---|---|
| Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) | 227 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| 10637_2018_Article_630.pdf | 160 |
| java.util.UUID:8d5f49e9-9a76-4e89-b6da-1e4fc51236db | 53 |
| java.util.UUID:7685d5f8-5f50-40ac-8518-6ad01437ea40 | 21 |
| java.util.UUID:2f8265e2-ed1f-4b9e-bc0b-fb5471a91436 | 6 |
Top country views
| views | |
|---|---|
| United States | 144 |
| Germany | 36 |
| United Kingdom | 5 |
| Ukraine | 5 |
| Malaysia | 4 |
| Sweden | 4 |
| Canada | 2 |
| France | 2 |
| Lebanon | 1 |
| Russia | 1 |
| Slovenia | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 55 |
| Gunzenhausen | 17 |
| Fairfield | 15 |
| Kiez | 14 |
| White Plains | 12 |
| Houston | 11 |
| Kansas City | 8 |
| Jacksonville | 6 |
| Cambridge | 5 |
| Kiev | 5 |
| Nürnberg | 4 |
| Stockholm | 4 |
| Seremban | 3 |
| Paris | 2 |
| San Francisco | 2 |
| Toronto | 2 |
| Warrington | 2 |
| Andover | 1 |
| Ashburn | 1 |
| Baltimore | 1 |
| Beirut | 1 |
| Brooklyn | 1 |
| Chicago | 1 |
| Endingen | 1 |
| Kuala Lumpur | 1 |
| Ljubljana | 1 |
| Moscow | 1 |
| Mountain View | 1 |
| New York | 1 |
| Phoenix | 1 |
| Sacramento | 1 |
| Scottsdale | 1 |
| Seattle | 1 |
| Washington | 1 |